240 related articles for article (PubMed ID: 35768005)
1. Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer.
Zhang R; Hohenforst-Schmidt W; Steppert C; Sziklavari Z; Schmidkonz C; Atzinger A; Kuwert T; Klink T; Sterlacci W; Hartmann A; Vieth M; Förster S
Nuklearmedizin; 2022 Oct; 61(5):385-393. PubMed ID: 35768005
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.
Seol HY; Kim YS; Kim SJ
Thorac Cancer; 2020 Nov; 11(11):3260-3268. PubMed ID: 32951338
[TBL] [Abstract][Full Text] [Related]
3. [Construction of A Nomogram Prediction Model for PD-L1 Expression
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
Hao L; Wang L; Zhang M; Yan J; Zhang F
Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
[TBL] [Abstract][Full Text] [Related]
4. The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT.
Monaco L; De Bernardi E; Bono F; Cortinovis D; Crivellaro C; Elisei F; L'Imperio V; Landoni C; Mathoux G; Musarra M; Pagni F; Turolla EA; Messa C; Guerra L
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3401-3411. PubMed ID: 35403860
[TBL] [Abstract][Full Text] [Related]
5. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
[TBL] [Abstract][Full Text] [Related]
6.
Hu B; Chen W; Zhang Y; Shi H; Cheng D; Xiu Y
Ann Nucl Med; 2020 May; 34(5):322-328. PubMed ID: 32130663
[TBL] [Abstract][Full Text] [Related]
7. Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.
Jiang M; Sun D; Guo Y; Guo Y; Xiao J; Wang L; Yao X
Acad Radiol; 2020 Feb; 27(2):171-179. PubMed ID: 31147234
[TBL] [Abstract][Full Text] [Related]
8. Association between
Zhao L; Liu J; Wang H; Shi J
Br J Radiol; 2021 Mar; 94(1119):20200397. PubMed ID: 33492995
[TBL] [Abstract][Full Text] [Related]
9. The correlation between PD-L1 expression and metabolic parameters of
Xu X; Li J; Yang Y; Sang S; Deng S
Clin Imaging; 2022 Sep; 89():120-127. PubMed ID: 35797878
[TBL] [Abstract][Full Text] [Related]
10. Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas.
Yoon J; Suh YJ; Han K; Cho H; Lee HJ; Hur J; Choi BW
Thorac Cancer; 2020 Apr; 11(4):993-1004. PubMed ID: 32043309
[TBL] [Abstract][Full Text] [Related]
11. Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer.
Miyazawa T; Otsubo K; Sakai H; Kimura H; Chosokabe M; Morikawa K; Furuya N; Marushima H; Kojima K; Mineshita M; Koike J; Saji H
Cancer Control; 2021; 28():10732748211038314. PubMed ID: 34384268
[TBL] [Abstract][Full Text] [Related]
12. Relationship between SP142 PD-L1 Expression and
Zhao L; Liu J; Shi J; Wang H
Contrast Media Mol Imaging; 2020; 2020():2010924. PubMed ID: 32765198
[TBL] [Abstract][Full Text] [Related]
13. A Machine Learning Approach Using PET/CT-based Radiomics for Prediction of PD-L1 Expression in Non-small Cell Lung Cancer.
Lim CH; Koh YW; Hyun SH; Lee SJ
Anticancer Res; 2022 Dec; 42(12):5875-5884. PubMed ID: 36456151
[TBL] [Abstract][Full Text] [Related]
14. A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer.
Zhou J; Zou S; Kuang D; Yan J; Zhao J; Zhu X
Front Oncol; 2021; 11():769272. PubMed ID: 34868999
[TBL] [Abstract][Full Text] [Related]
15. Association Between PD-L1 Expression and Metabolic Activity on
Takada K; Toyokawa G; Tagawa T; Kohashi K; Akamine T; Takamori S; Hirai F; Shoji F; Okamoto T; Oda Y; Maehara Y
Anticancer Res; 2017 Dec; 37(12):7073-7082. PubMed ID: 29187498
[TBL] [Abstract][Full Text] [Related]
16. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
17. The Value of
Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
[TBL] [Abstract][Full Text] [Related]
18. Developing a primary tumor and lymph node 18F-FDG PET/CT-clinical (TLPC) model to predict lymph node metastasis of resectable T2-4 NSCLC.
Wang M; Liu L; Dai Q; Jin M; Huang G
J Cancer Res Clin Oncol; 2023 Jan; 149(1):247-261. PubMed ID: 36565319
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.
Wang D; Li Y; Chen X; Li P
Medicine (Baltimore); 2021 Sep; 100(35):e27100. PubMed ID: 34477147
[TBL] [Abstract][Full Text] [Related]
20.
Jreige M; Letovanec I; Chaba K; Renaud S; Rusakiewicz S; Cristina V; Peters S; Krueger T; de Leval L; Kandalaft LE; Nicod-Lalonde M; Romero P; Prior JO; Coukos G; Schaefer N
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1859-1868. PubMed ID: 31214790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
